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Autosomal-recessive inheritance accounts for nearly 25% of nonsyndromic mental retardation (MR), but the extreme heterogeneity of
such conditions markedly hampers gene identiﬁcation. Combining autozygosity mapping and RNA expression proﬁling in a consan-
guineous Tunisian family of three MR children with mild microcephaly and white-matter abnormalities identiﬁed the TRAPPC9
gene, which encodes a NF-kB-inducing kinase (NIK) and IkB kinase complex b (IKK-b) binding protein, as a likely candidate. Sequencing
analysis revealed a nonsense variant (c.1708C>T [p.R570X]) within exon 9 of this gene that is responsible for an undetectable level of
TRAPPC9 protein in patient skin ﬁbroblasts. Moreover, TNF-a stimulation assays showed a defect in IkBa degradation, suggesting
impaired NF-kB signaling in patient cells. This study provides evidence of an NF-kB signaling defect in isolated MR.Mental retardation (MR) is characterized by a broad range
of cognitive-function deﬁcits that signiﬁcantly hamper
adaptive capacities required for daily living, communica-
tion, social interaction and integration, self-direction,
and work.1 It is the most frequent handicap in children
and young adults, affecting 2%–3% of the general popula-
tion.2 The severity of MR is commonly classiﬁed on the
basis of the intelligence quotient (IQ), although other
criteria have also been used. With the assumption of a
population mean of 100 and a standard deviation of 15,
MR is usually classiﬁed as ‘‘mild’’ when the IQ value ranges
between 50 and 70 and as ‘‘severe’’ when the IQ value is
below 50. Finally, MR is also subdivided into syndromic
and nonsyndromic forms, depending on whether addi-
tional abnormalities are found on physical examination,
laboratory investigation, or brain imaging.
These deﬁnitions hide a much more complex situation,
and little is known about the biological bases of MR.
Indeed, despite recent advances in cytogenetic and molec-
ular genetic technologies, the cause of the mental hand-
icap remains unexplained in 40% of the cases, leaving
families with neither accurate diagnosis nor genetic coun-
seling. Understanding the biological bases of these disor-
ders is therefore a major challenge for the next years.
An autosomal-recessive mode of inheritance accounts
for largely 25% of unexplained MR. Although X-linked
MR has been extensively studied in the last decade, very
little is known about the autosomal-recessive form of MR,
which is far more common than X-linked forms. The broad
genetic heterogeneity of autosomal-recessive MR (ARMR)
has prevented researchers from pooling families, and the
scarcity of large pedigrees has hitherto hampered the iden-
tiﬁcation of disease genes. Yet, autozygosity mapping inlarge consanguineous families has led to the identiﬁca-
tion of ﬁve genes responsible for nonsyndromic ARMR:
PRSS12, on chromosome 4q26 (MIM 606709);3 CRBN, on
chromosome 3p26 (MIM 607417);4 CC2D1A, on chromo-
some 19p13.12 (MIM 608443);5 GRIK2, on chromosome
6q21 (MIM 611092);6 and TUSC3, on chromosome 8p22
(MIM 611093).7,8 Moreover, ten loci have been mapped,
but each of these genes or loci accounts for only one or
very few families, suggesting that many disease-causing
genes remain to be characterized.9,10
We ascertained a sibship of three affected boys and one
healthy boy born to healthy Tunisian parents who are ﬁrst
cousins (Figure 1A). Institutional ethical approval for
research and written consent were obtained for all partici-
pants in the study. All patients were born within normal
growth parameters after an unremarkable pregnancy and
delivery. The neonatal period was uncomplicated. Devel-
opmental delay became obvious by the end of the ﬁrst
year, and a signiﬁcant speech delay was noted thereafter.
The older affected brother, patient V-1, was ﬁrst examined
at the age of 10 yrs. He was a friendly, severely mentally
retarded patient with a developmental IQ estimated by
standardized tests to be 34. Physical examination revealed
a mild microcephaly (occipitofrontal circumference [OFC]
49.5 cm, 2 standard deviations [SD]), truncular obesity,
hypertelorism, short neck, and prominent upper central
incisors. At 19 yrs of age, his height was 167 cm (1 SD)
and OFC was 53 cm (2 SD). He showed mildly dysmor-
phic facial features, with short and smooth philtrum.
Chromosome analysis, array-CGH testing at 1 Mb resolu-
tion, metabolic screening, and molecular testing for
fragile X and FRAXE syndromes were all normal. Brain
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abnormalities with discordance between T2 and FLAIR
sequences (Figure 1B). Indeed, whereas normal myelina-
tion was observed on T2 sequence, FLAIR sequence
showed important white-matter abnormalities when
compared to a control. Patient V-2 had surgery for unilat-
eral labial cleft. He walked at 17 mo of age. His speech
was delayed, his ﬁrst words being spoken at age 3. At the
age of 7 yrs, his height was 122 cm (þ0.5 SD), weight
was 30 kg (þ3 SD), and OFC was 49 cm (1 SD). He pre-
sented with truncular obesity and midly dysmorphic
features including hypotelorism, short neck, and promi-
nent upper central incisors. Happy disposition and hyper-
activity were noted. When examined at age 15, he was
observed to be a friendly, moderately mentally retarded
patient with a slender posture. His height was 172 cm
(þ1 SD), weight was 50 kg (1 SD), and OFC was 50 cm
(< 3 SD). He had mildly dysmorphic facial features,
with short and smooth philtrum and long and thin ﬁngers.
Figure 1. Pedigree of the Family and
Brain MRI Features
(A) Pedigree of the family. Shaded symbols
indicate individuals presenting with MR.
(B) Discordance between T2 and FLAIR
sequences in patients V-1 and V-4. Coronal
T2 weighted image (left) and coronal
FLAIR image (right) of patient V-4 (upper
panels) and patient V-1 (middle panel) at
the level of the third ventricle demonstrate
normal myelination on T2 sequence. By
contrast, FLAIR sequence shows important
white-matter abnormalities (white arrow)
at the sus tentorial level compared to a
normal control (lower panels).
He understood simple commands
and concrete tasks and communi-
cated verbally, with a low vocabulary
and simple sentence structures. The
third affected child (patient V-4)
had global developmental delay but
was less severely affected than his
brothers. When examined at the age
of 4 yrs, he was able to communicate
verbally with about twenty words,
understood commands, and was able
to performed simple tasks. A hyperac-
tive behavior was noted. His height
was 102 cm, weight was 22 kg (with
truncular obesity), and OFC was
48.5 cm (2 SD). Brain MRI showed
white-matter abnormalities similar
to those observed for patient V-1,
with discordance between T2 and
FLAIR sequences (Figure 1B). Finally,
we investigated the X chromosome
inactivation proﬁle in the mother by
methyl-sensitive PCR analysis and
observed that she showed a random X chromosome inac-
tivation proﬁle (58/42).
In conclusion, MR associated with mild microcephaly,
myelination defect, and truncular obesity in the ﬁrst year
were consistent features in the three affected siblings.
Blood samples were collected from all affected and unaf-
fected siblings and both parents, and skin ﬁbroblasts were
cultured from patient V-1. For genome-wide autozygosity
screen, genomic DNA was extracted by standard methods
and analyzed with the Affymetrix GeneChip Mapping
10K Array. Multipoint linkage analysis resulted in two
signiﬁcant linkage peaks on chromosomes 8 and X, respec-
tively (Figure 2A). Further genotype and haplotype anal-
yses conﬁrmed homozygosity by descent and deﬁned
a 12 Mb critical interval between markers rs2395855
and rs1397380 on 8q24 (LOD scores 3.13) and a 30 Mb
critical interval between markers rs982833 and rs750841
on Xq25-q28 (LOD scores 0.9) (Figure S1, available online).904 The American Journal of Human Genetics 85, 903–908, December 11, 2009
No other genomic regions were consistent with linkage.
Altogether these two regions encompassed 172 known
genes (NCBI build 36.3), the majority of which are
expressed in the brain. The coding sequence of 14 candi-
date genes on 8q24 and three candidate genes on Xq25-
q28 (Table S1) was searched for variants at DNA and/or
RNA levels, but no causative mutation was identiﬁed in
any of these genes. Thus, to prioritize the remaining candi-
date genes for sequencing, we hypothesized that the
disease-gene transcript could be downregulated in affected
subjects. RNA was extracted from skin ﬁbroblasts derived
from patient V-1 and from three healthy gender-matched
control ﬁbroblasts and analyzed with Affymetrix U133
Plus2 array. Microarray analysis was performed with
bioconductor packages for the R programming environ-
ment. Background subtraction, normalization, and probe
summarization were done with GeneChip robust multiar-
Figure 2. Genetic Analysis of the Family
(A) Results of the linkage analysis with the
Merlin software. The y axis represents
the LOD score and the x axis represents
the genetic distance.
(B) Quantitative PCR analysis of TRAPPC9
mRNA. TRAPPC9 expression in ﬁbroblast
cells from two controls (black and gray
bars) and patient V-1 is shown. Data are
normalized to beta2 microglobuline (B2M)
andGlyceraldehyde 3-phosphate dehydro-
genase (GAPDH). Means5 standard devia-
tion are given (n ¼ 5 independent experi-
ments). ***Signiﬁcance of difference with
control values (Student’s test), p < 0.01.
(C) Electrophoregrams illustrating the
c.1708C>T variant in the TRAPPC9 gene.
Data are shown for a control, an affected
child (V-1), and a healthy heterozygote
parent (IV-1). The position of the single-
nucleotide change is shown by a black
arrow.
ray averaging (gcrma), and tests of
signiﬁcance were conducted with
the local pooled error (LPE) test.11
Analysis was conﬁned to the probe
sets mapping to the two regions
deﬁned by genetic linkage analyses,
and TRAPPC9 (also known as NIBP,
NIK, and IKK-b Binding Protein, MIM
611966), located on chromosome
8q24, appeared as a good candidate.
Indeed, it was signiﬁcantly downregu-
lated (40%) in the proband compared
to controls (p ¼ 4.0 3 1014). A 90%
TRAPPC9mRNA decay was conﬁrmed
by quantitative RT-PCR (Figure 2B),
and subsequent mutational analyses
identiﬁed a homozygote nonsense
variant (c.1708C>T, p.R570X) within
exon 9 of the gene (Figure 2C). This
variant cosegregated with the disease and was not found
in 1120 control chromosomes, including 196 chromo-
somes from individuals of Tunisian origin, supporting the
hypothesis that the p.R570X change is the disease-causing
mutation. Homozygosity at the TRAPPC9 locus was tested
by genotyping with Affymetrix GeneChip Mapping 250K
array in thirteen independent consanguineous MR
patients. However, no patient was found to be compatible
with linkage to this locus.
For the evaluation of the consequence of the c.1708C>T
mutation on protein expression, immunoblots were then
prepared with ﬁbroblast cell lysates from the affected sib
and two healthy controls and probed with a polyclonal
anti-TRAPPC9 antibody raised against the complete
protein. Whereas TRAPPC9 was clearly detectable in cell
lysates from healthy controls as a single band, neither
normal nor shortened protein was found in ﬁbroblast cellThe American Journal of Human Genetics 85, 903–908, December 11, 2009 905
Figure 3. Functional Consequences of
the TRAPPC9 Mutation
(A) Immunoblot analysis of TRAPPC9
protein. Lysates from controls (C1-2) and
patient (V-1) ﬁbroblasts were subjected to
immunoblotting with a polyclonal anti-
b-actin antibody as a loading control
(lower panel) and with a rabbit polyclonal
anti-TRAPPC9 antibody (upper panel).
Molecular weights are indicated on the
left. TRAPPC9, shown as a 140 kD band
in controls, is absent in the patient.
(B) Time-course analysis of TNF-a-induced
IkB-a degradation as detected by immuno-
blot. Lysates were subjected to immuno-
blotting with a polyclonal anti-b-actin antibody as a loading control (lower panel) and with a rabbit polyclonal anti-IKB-a antibody
(upper panel). IKB-a is shown as a 37 kD band. Results from one representative experiment are shown.extracts from the patient (Figure 3A). Taken together, these
results suggest that the mutation causes a nonsense-medi-
ated mRNA decay.
TRAPPC9 has been originally identiﬁed as a protein that
interacts with the nuclear factor kappaB (NF-kB)-inducing
kinase (NIK) and IkB kinase complex b (IKK-b).12 The
NF-kB transcription factor (TF) is a ubiquitously expressed
dimeric molecule that regulates the expression of a variety
of genes and plays a key role in a number of cellular
processes such as innate and adaptive immunity, cellular
proliferation, apoptosis, and development. In mammals,
the NF-kB family is composed of ﬁve related transcription
factors: p50, p52, RelA, c-Rel, and RelB.13 These proteins
form homo- or heterodimers that are retained in the cyto-
plasm by interaction with inhibitory molecules (IkBs).14
Activation of NF-kB is mediated by both canonical and
noncanonical signaling pathways.15–17 The canonical
pathway signals through activation of an IkB kinase (IKK)
complex, composed of two catalytic subunits, IKK-a and
IKK-b, and a regulatory subunit, NF-kB essential modulator
(NEMO)/IKK-g. Upon stimulation, this complex triggers
phosphorylation of the IkBs, leading to their ubiquitina-
tion and degradation through the proteasome pathway.
Freed p50-RelA and p50-cRel dimers then migrate to the
nucleus. The noncanonical pathway involves phosphory-
lation of IKK-a by NIK, which then triggers inducible
processing of the p100, causing the release of a p52/RelB
active heterodimer TF. On the basis of its interaction with
NIK and IKK-b proteins, a role in both canonical and non-
canonical NF-kB pathways was proposed for TRAPPC9.12
To further evaluate the functional consequences of
the p.R570X mutation on NF-kB signaling pathway,
we analyzed the response of cultured skin ﬁbroblasts of
patient V-1 to TNF-a, a powerful activator of the NF-kB
system. Cultured ﬁbroblasts from controls and a patient
were stimulated for various times with 10 ng/ml of TNF-a.
The time course of degradation of the inhibitory protein
IkB-a was then analyzed by immunoblotting. Figure 3B
shows a slight decrease in the level of IkB-a after 10 and
20 min of TNF-a stimulation in patient skin ﬁbroblasts,
whereas IkB-a almost completely disappeared in ﬁbroblasts906 The American Journal of Human Genetics 85, 903–908, Decembfrom two independent healthy controls. These results
support the hypothesis of an impaired of NF-kB signaling
in cells carrying the p.R570X mutation.
NF-kB activity and expression of several NF-kB target
genes are altered in many chronic neurodegenerative
diseases such as Alzheimer’s disease,18 Parkinson’s disease,
andHuntington’s disease.19,20 To our knowledge, this study
provides the ﬁrst evidence of a NF-kB signaling defect in an
isolated cognitive deﬁcit. How a TRAPPC9mutation caused
isolated MR remains questionable. Previous studies have
demonstrated that knocking down TRAPPC9 expression
prevented nerve growth factor-induced neuronal differen-
tiation and suggested that TRAPPC9 might function as
a downstream component of the NGF pathway.12 Yet how
absence of TRAPPC9 protein led to MR in our patient
remains unexplained.
Cognitive dysfunction is generally regarded as the conse-
quence of a defect in synapse formation and plasticity.
Along these lines, it is worth remembering that subcellular
distribution, DNA binding activity, and transcription of
NF-kB are regulated by various forms of synaptic activity
and that this TF plays an important role in the induction
of synaptic plasticity and long-term-memory forma-
tion.21,22 Inhibition of NF-kB blocked induction of long-
term potentiation (LTP) in the hippocampus and amyg-
dala.23,24Moreover, exposure toexogenousTNF-a inhibited
induction of LTP, and the knockout of TNF receptors
inhibited induction of long-term depression (LTD).23,25
Finally, recent studies based on cell-restricted ablation
of NF-kB subunits demonstrated the prominent role of
neuronal NF-kB in memory and cognition and indicated
that NF-kB activation is essential for long-term-memory
formation, especially when hippocampus is involved.26
Impaired NF-kB signaling in glial cells may also play an
important role in the pathogenesis of the disease, given
that recent data suggest an active role of astrocytes and
oligodendrocytes in synaptic transmission.27 Constitutive
TNF-a release by glial cells promoted upregulation of
AMPA receptors and internalization of inhibitory GABA
receptors in hippocampal neurons, thereby increasing
synaptic strength.28,29er 11, 2009
Finally, our study may shed light on the role of NF-kB in
the myelination process in the CNS. Although NF-kB has
been shown to orchestrate the axon myelination of
peripheral neurons by Schwann cells,30 whether it plays
a similar critical role in the differentiation of oligodendro-
cytes remains to be establish. The brainMRI observation of
a myelination defect in our patients may provide further
support to this hypothesis.
In conclusion, our study provides evidence that a NF-kB
signaling defect may cause isolated cognitive deﬁcit, ex-
panding therefore the ﬁeld of the pathophysiology of MR.
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